Examining the utility of patient-derived xenograft mouse models (original) (raw)

• DeRose, Y. S. et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nature Med. 17, 1514–1520 (2011).
  Article CAS PubMed Google Scholar
• Zhang, X. et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 73, 4885–4897 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Zhao, X. et al. Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma. Neuro Oncol. 14, 574–583 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Loukopoulos, P. et al. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas 29, 193–203 (2004).
  Article CAS PubMed Google Scholar
• Kabos, P. et al. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res. Treat. 135, 415–432 (2012).
  Article CAS PubMed Google Scholar
• Eirew, P. et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 518, 422–426 (2015).
  Article CAS PubMed Google Scholar
• Shah, S. P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395–399 (2012).
  CAS PubMed Google Scholar
• Roth, A. et al. PyClone: statistical inference of clonal population structure in cancer. Nature Meth. 11, 396–398 (2014).
  Article CAS Google Scholar
• Ding, L. et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999–1005 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Hidalgo, M. et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 4, 998–1013 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Reyal, F. et al. Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res. 14, R11 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Garrido-Laguna, I. et al. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin. Cancer Res. 17, 5793–5800 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Martinez-Garcia, R. et al. Transcriptional dissection of pancreatic tumors engrafted in mice. Genome Med. 6, 27 (2014).
  Article PubMed PubMed Central Google Scholar
• Kung, A. L. Practices and pitfalls of mouse cancer models in drug discovery. Adv. Cancer Res. 96, 191–212 (2007).
  Article CAS PubMed Google Scholar
• Johnson, J. I. et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 84, 1424–1431 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Bertotti, A. et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 1, 508–523 (2011).
  Article CAS PubMed Google Scholar
• Marangoni, E. et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin. Cancer Res. 13, 3989–3998 (2007).
  Article CAS PubMed Google Scholar
• Fichtner, I. et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin. Cancer Res. 14, 6456–6468 (2008).
  Article CAS PubMed Google Scholar
• Sivanand, S. et al. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci. Transl. Med. 4, 137ra75 (2012).
  Article PubMed PubMed Central Google Scholar
• Julien, S. et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin. Cancer Res. 18, 5314–5328 (2012).
  Article CAS PubMed Google Scholar
• Peterson, J. K. & Houghton, P. J. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur. J. Cancer 40, 837–844 (2004).
  Article CAS PubMed Google Scholar
• Hidalgo, M. et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol. Cancer Ther. 10, 1311–1316 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Morelli, M. P. et al. Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. J. Clin. Oncol. 30, e45–e48 (2012).
  Article CAS PubMed Google Scholar
• Garralda, E. Integrated next generation sequencing and ¨avatar¨ mouse models for personalized cancer treatment. J. Clin. Oncol. 13, 2476–2484 (2013).
  Google Scholar
• Crystal, A. S. et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346, 1480–1486 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Boven, E. et al. Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study. Cancer Res. 52, 5940–5947 (1992).
  CAS PubMed Google Scholar
• Hammer, S. et al. Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer. Clin. Cancer Res. 16, 1452–1465 (2010).
  Article CAS PubMed Google Scholar
• Boj, S. F. et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160, 324–338 (2015).
  Article CAS PubMed Google Scholar
• Gao, D. et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 159, 176–187 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Karthaus, W. R. et al. Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell 159, 163–175 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Li, X. et al. Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. Nature Med. 20, 769–777 (2014).
  Article CAS PubMed Google Scholar
• Baccelli, I. et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nature Biotech. 31, 539–544 (2013).
  Article CAS Google Scholar
• Vidal, A. et al. Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer. Clin. Cancer Res. 18, 5399–5411 (2012).
  Article CAS PubMed Google Scholar
• Lock, R. B., Liem, N. L. & Papa, R. A. Preclinical testing of antileukemic drugs using an in vivo model of systemic disease. Methods Mol. Med. 111, 323–334 (2005).
  CAS PubMed Google Scholar
• Kalscheuer, H. et al. A model for personalized in vivo analysis of human immune responsiveness. Sci. Transl. Med. 4, 125ra30 (2012).
  Article PubMed PubMed Central Google Scholar
• Kreso, A. et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 339, 543–548 (2013).
  Article CAS PubMed Google Scholar
• Marusyk, A. et al. Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature 514, 54–58 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Bardelli, A. et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 3, 658–673 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Alvarez, R. et al. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br. J. Cancer 109, 926–933 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Von Hoff, D. D. et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J. Clin. Oncol. 29, 4548–4554 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691–1703 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Krumbach, R. et al. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur. J. Cancer 47, 1231–1243 (2011).
  Article CAS PubMed Google Scholar